Clinical Trial Search

Primary: Number of Subjects With Improvement in Global Facial Aesthetic Appearance at 7 Months (Review of Photographs) — 20; 25 Participants

Primary: Number of Participants Who Show Stability, Improvement or Decline in Self Reported Hearing — 13; 18; 0 Participants

Primary: Number of Participants Responding Affirmatively to at Least One Whooley Question According to Survey Layout — 62; 60 Participants — p=0.994

Primary: Number of Subjects With Anti-hepatitis A Virus (HAV) Seropositivity Status at Approximately 8 Years Following Last Administered Havrix Dose — 223; 293; 77; 7 Participants

Primary: Symptom-free Days in the Last 14 Days — 11.4; 11.6 days in prior 14d — p=0.93

Primary: Post-operative Plasma IL-6 — 126; 111 pg/ml — p=0.09

Primary: Effects of a Multimodal Pulmonary Rehabilitation Program on 6 Minute Walking Distance (6MWD) — 35; 36 meter

Primary: Weekly Health Appointment Measure — 6.33; 3.42; 8.64; 4.65 appointments — p=.04

Primary: Change in Cognitive Function as Measured Using the Extended Mini Mental State Exam — 0.58 Change on a scale

Primary: Number of Participants With Complete Response at 3 Months — 26 Participants

Primary: Phase A: Number of Subjects With Confirmed Varicella Case — 37; 243; 201 Participants — p=<0.0001

Primary: Number of Subjects With Treatment-emergent Adverse Events (TEAEs) — 3; 4; 6; 40 Participants

Primary: Maximum Tolerated Dose (MTD) of Olaparib — 50 mg twice daily

Primary: Probability of Target Attainment for 40% fT>MIC — 100; 100 percentage of time above MIC

Primary: Objective Response Rate (ORR), Defined as the Proportion of Patients Who Have Had a Partial Response (PR) or Complete Response (CR) (RECIST 1.1 Based) Within the First 6…